Page 1

idogen Idogen AB Interim report January 1 - June 30 , 2021 " " Tolerogenic cell therapy has the potential to improve and prolong the life of many patients with immune driven conditions and diseases . Idogen aims to play a key role in the rapid development that is taking place in the field . " Idogen AB ( publ ) Corp. Reg . no . 556756-8521 www.idogen.com Anders Karlsson , CEO